Setsi sa Kankere sa John Theurer Setsing sa Bongaka sa Univesithi ea Hackensack se phatlalalitse kajeno hore se alafa mokuli oa pele ka har'a naha ka DSP-0390, setlhare se secha sa lipatlisiso sa glioblastoma (GBM) le li-gliomas tse ling tsa anaplastic.

Glioblastoma (GBM) ke e 'ngoe ea mefuta e mabifi ka ho fetisisa ea mofetše oa boko o atisang ho ipheta ho sa tsotellehe mekhoa e tloaelehileng ea phekolo e kang chemotherapy le radiation. Ho phela ka mor'a lilemo tse hlano ha hoa tloaeleha, 'me phekolo e ncha e hlokahala haholo.

DSP-0390, moemeli e mocha oa lipatlisiso o entsoeng ke Cambridge, Massachusetts-based Sumitomo Dainippon Pharma Oncology, ke inhibitor ea emopamil-binding protheine (EBP), molek'hule ho cholesterol biosynthesis. DSP-0390 ha e so amoheloe ke Tsamaiso ea Lijo le Lithethefatsi ea US ebile ha e so thehoe polokeho le katleho ea eona.

"'Mele ea rona e hloka k'holeseterole ho haha lisele tse phetseng hantle le hore lisele tseo li tšoaetsane," ho boletse Samuel A. Goldlust, MD, Mookameli oa Bongaka oa Neuro-Oncology. "Empa lisele tsa GBM li ka qobella tlhahiso ea k'holeseterole ho feta tekano, e leng se lebisang ho holeng ha hlahala le ho thibela EPB ho ka thibela kholo ena."

Boithuto bona ba lefatše ka bophara ba Phase 1/2 bo reretsoe ho ngolisa bakuli ba 70 litsing tse hlano tsa hlahala ea boko US le Japane.

"Liteko tsa bongaka tsa GBM li re rutile hore phekolo ea setso ha ea lekana ho hlōla hlahala ena e phephetsang," ho boletse George J. Kaptain MD, Mookameli oa Neurosurgical Oncology. "Ke tokelo ho khona ho fa bakuli ba rona monyetla oa ho fumana litlhare tse mabapi le limolek'hule tse kang DSP -0390, ts'ebetsong ea rona e tsoelang pele ea kalafo ho thusa ho phela le ho fokotsa litlamorao."

SEO U LOKELANG HO SE NKA HO SEHLOOHO ENA:

“It is a privilege to be able to offer our patients streamlined access to novel, investigational molecularly targeted therapies like DSP -0390, in our ongoing pursuit of treatments to help maximize survival and minimize side effects.
DSP-0390, an investigational new agent developed by Cambridge, Massachusetts-based Sumitomo Dainippon Pharma Oncology, is an inhibitor of emopamil-binding protein (EBP), a molecule in cholesterol biosynthesis.
This multicenter, global Phase 1/2 study is planned to enroll 70 patients at five brain tumor centers in the U.